a cornerstone of future treatment.”
McCann said that the next step is to focus on bringing reSET into the hands of patients and clinicians. He hopes Pear Therapeutics will officially launch the product over the next six months.
The FDA’s approval “is really an amazing moment,” he said. “To put it into perspective, this the first time the FDA has approved something like this, especially in addiction treatment.”
